BioNTech SE (BNTX) EBITDA (2018 - 2025)
BioNTech SE (BNTX) posted EBITDA of -$375.8 million for Q4 2025, down 585.32% sequentially from -$54.8 million in Q3 2025, and down 336.63% YoY from $158.8 million in Q4 2024.
BioNTech SE (BNTX) EBITDA (2018 - 2025) Analysis & Trends
BioNTech SE has reported EBITDA for 8 years, with the latest figure at -$375.8 million in Q4 2025.
- Quarterly EBITDA fell 336.63% year-over-year to -$375.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.6 billion (down 9.74% YoY) and the FY2025 annual result came in at -$1.6 billion, down 13.02% from the prior year.
- EBITDA declined to -$375.8 million in Q4 2025 per BNTX's latest filing, from -$54.8 million in the prior quarter.
- Over five years, EBITDA peaked at $6.1 billion in Q1 2022 and troughed at -$1.0 billion in Q2 2024.
- A 5-year average of $1.4 billion and a median of $119.2 million in 2023 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA jumped 62488226.12% in 2022, then tumbled 575.48% in 2025.
- Over 5 years, EBITDA stood at $5376.3 in 2021, then surged by 62488226.12% to $3.4 billion in 2022, then tumbled by 83.15% to $566.2 million in 2023, then slumped by 71.95% to $158.8 million in 2024, then tumbled by 336.63% to -$375.8 million in 2025.
- According to Business Quant data, EBITDA over the past three periods registered -$375.8 million, -$54.8 million, and -$567.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | -375.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -375.75 Mn |
| Sep 30, 2025 | -54.83 Mn |
| Jun 30, 2025 | -567.22 Mn |
| Mar 31, 2025 | -561.81 Mn |
| Dec 31, 2024 | 158.79 Mn |
| Sep 30, 2024 | 11.53 Mn |
| Jun 30, 2024 | -1.04 Bn |
| Mar 31, 2024 | -551.00 Mn |
| Dec 31, 2023 | 566.16 Mn |
| Sep 30, 2023 | 79.58 Mn |
| Jun 30, 2023 | -613.39 Mn |
| Mar 31, 2023 | 702.39 Mn |
| Dec 31, 2022 | 3.36 Bn |
| Sep 30, 2022 | 3.22 Bn |
| Jun 30, 2022 | 5.07 Bn |
| Mar 31, 2022 | 6.12 Bn |
| Dec 31, 2021 | 5.38 Bn |
| Sep 30, 2021 | 5.57 Bn |
| Jun 30, 2021 | 5.06 Bn |
| Mar 31, 2021 | 2.01 Bn |